Please check your internet connection and try again.
# Meftal-Spas
## Overview
Meftal-Spas is a fixed-dose combination medication containing **Mefenamic Acid** (250 mg), an NSAID, and **Dicyclomine Hydrochloride** (10 mg), an antispasmodic/anticholinergic. It is commonly used for the management of abdominal pain associated with smooth muscle spasms.
## Primary Indications
* Dysmenorrhea (primary).
* Abdominal pain secondary to gastrointestinal smooth muscle spasms.
* Colicky pain.
## Adult Dosing
* **Standard Dose:** 1 tablet (250 mg Mefenamic Acid / 10 mg Dicyclomine) taken orally 3 to 4 times daily as needed.
* **Maximum Dose:** Do not exceed 4 tablets in 24 hours. Limit therapy to the shortest duration possible (typically 3–5 days).
## Pediatric Dosing
* **Safety Note:** Use is generally **not recommended** in children due to the risks associated with NSAIDs and the anticholinergic effects of dicyclomine.
* **If prescribed:** Dosing should be strictly weight-based and determined by a pediatrician. There is no standard universal pediatric guideline for this combination; utilize local hospital protocols.
## Dose Adjustments
* **Renal Impairment:** Contraindicated or requires extreme caution in patients with severe renal impairment (CrCl < 30 mL/min).
* **Hepatic Impairment:** Avoid in patients with active liver disease.
* **Elderly:** Use with caution; increased risk of anticholinergic side effects (confusion, urinary retention, constipation) and NSAID-related GI toxicity.
## Contraindications
* Hypersensitivity to Mefenamic Acid, Dicyclomine, or aspirin/NSAIDs.
* Active peptic ulceration or gastrointestinal bleeding.
* History of asthma or urticaria triggered by aspirin/NSAIDs.
* Obstructive uropathy or gastrointestinal obstruction (due to dicyclomine).
* Severe ulcerative colitis or inflammatory bowel disease.
* Perioperative use in the setting of coronary artery bypass graft (CABG) surgery.
## Adverse Effects
* **Mefenamic Acid (NSAID):** GI upset, ulceration, bleeding, nephrotoxicity, cardiovascular risk (thrombotic events).
* **Dicyclomine (Anticholinergic):** Dry mouth, blurred vision, tachycardia, lightheadedness, urinary retention, constipation, and drowsiness.
## Key Drug Interactions
* **Anticoagulants (Warfarin/Heparin):** Increased risk of bleeding.
* **Antihypertensives (ACE inhibitors/Diuretics):** Decreased efficacy and increased risk of acute kidney injury.
* **CNS Depressants:** Enhanced sedative effects due to dicyclomine.
* **Other Anticholinergics:** Added risk of urinary retention and cognitive impairment.
* **Lithium/Methotrexate:** Potential for increased serum concentrations and toxicity.
## Monitoring
* Monitor for signs of GI bleeding (melena, hematemesis).
* Monitor blood pressure periodically.
* Assess renal function if long-term use is mistakenly considered.
* Observe for anticholinergic toxicity (extreme dry mouth, urinary retention, confusion).
## Clinical Pearls
* **Administration:** Take with food or milk to minimize gastric irritation.
* **Warning:** Advise patients to avoid driving or operating heavy machinery if they experience drowsiness or blurred vision secondary to dicyclomine.
* **Pregnancy/Lactation:** Generally avoided; Mefenamic acid is contraindicated in the third trimester due to risk of premature closure of the ductus arteriosus.
* **Disclaimer:** This is a fixed-dose combination. In many practice settings, monotherapy for pain is preferred to avoid unnecessary exposure to an anticholinergic if only an analgesic is required.
***
**Educational Disclaimer:** This information is for educational purposes only and does not replace professional clinical judgment. Prescribing practices vary by region and institutional protocol. Always verify current prescribing information, contraindications, and patient-specific factors via official drug monographs (e.g., electronic prescribing databases or local formularies) before administering any medication.
